BRPI0510666A - compostos de amida de arila ou heteroarila de metila substituìda, composições farmacêuticas compreendendo os mesmos, uso e combinação - Google Patents
compostos de amida de arila ou heteroarila de metila substituìda, composições farmacêuticas compreendendo os mesmos, uso e combinaçãoInfo
- Publication number
- BRPI0510666A BRPI0510666A BRPI0510666-4A BRPI0510666A BRPI0510666A BR PI0510666 A BRPI0510666 A BR PI0510666A BR PI0510666 A BRPI0510666 A BR PI0510666A BR PI0510666 A BRPI0510666 A BR PI0510666A
- Authority
- BR
- Brazil
- Prior art keywords
- combination
- substituted aryl
- pharmaceutical compositions
- amide compounds
- heteroaryl amide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Abstract
COMPOSTOS DE AMIDA DE ARILA OU HETEROARILA DE METILA SUBSTITUìDA, COMPOSIçõES FARMACêUTICAS COMPREENDENDO OS MESMOS, USO E COMBINAçãO. A presente invenção refere-se a um composto da fórmula (I): em que X representa um átomo de carbono ou similares: Y representa imino, e similares: R¬ 1¬ representa um grupo de alquila possuindo de 1 a 6 átomos de carbono ou similares: R¬ 2¬ e R¬ 3¬ independentemente representa um átomo de hidrogênio ou similares. Estes compostos são úteis para o tratamento de condições de doença mediadas por prostaglandina tais como dor, ou similares em mamífero. Esta invenção também fornece uma composição farmacêutica compreendendo o composto acima.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56808804P | 2004-05-04 | 2004-05-04 | |
PCT/IB2005/001134 WO2005105732A1 (en) | 2004-05-04 | 2005-04-22 | Substituted methyl aryl or heteroaryl amide compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0510666A true BRPI0510666A (pt) | 2007-12-04 |
Family
ID=34982397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0510666-4A BRPI0510666A (pt) | 2004-05-04 | 2005-04-22 | compostos de amida de arila ou heteroarila de metila substituìda, composições farmacêuticas compreendendo os mesmos, uso e combinação |
Country Status (29)
Country | Link |
---|---|
US (2) | US7534914B2 (pt) |
EP (1) | EP1756042B8 (pt) |
JP (1) | JP4054368B2 (pt) |
KR (1) | KR20070006891A (pt) |
CN (1) | CN1950333A (pt) |
AP (1) | AP2006003785A0 (pt) |
AR (1) | AR048642A1 (pt) |
AU (1) | AU2005238291A1 (pt) |
BR (1) | BRPI0510666A (pt) |
CA (1) | CA2565813C (pt) |
CR (1) | CR8730A (pt) |
DO (1) | DOP2005000071A (pt) |
EA (1) | EA200601847A1 (pt) |
EC (1) | ECSP066968A (pt) |
ES (1) | ES2461265T3 (pt) |
GT (1) | GT200500101A (pt) |
IL (1) | IL178676A0 (pt) |
MA (1) | MA28571B1 (pt) |
MX (1) | MXPA06011555A (pt) |
NL (1) | NL1028947C2 (pt) |
NO (1) | NO20065578L (pt) |
PA (1) | PA8631201A1 (pt) |
PE (1) | PE20060306A1 (pt) |
SV (1) | SV2005002102A (pt) |
TN (1) | TNSN06358A1 (pt) |
TW (1) | TW200536541A (pt) |
UY (1) | UY28877A1 (pt) |
WO (1) | WO2005105732A1 (pt) |
ZA (1) | ZA200608393B (pt) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007035789A1 (en) * | 2005-09-19 | 2007-03-29 | Teva Pharmaceutical Industries Ltd. | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the new synthesis of (s)-pregabalin |
DE102005062966A1 (de) * | 2005-12-28 | 2007-07-05 | Basf Ag | Verfahren zur Herstellung von (R)- und (S)-4-(Ammoniumethyl)benzoesäuremethylester-sulfat |
EP1969129B1 (de) | 2005-12-28 | 2009-03-11 | Basf Se | Verfahren zur herstellung von (r)- und (s)-4-(1-aminomethyl)benzoesäuremethylester-sulfat aus racemischem 4-(1-amin0ethyl)benzoesäuremethylester |
UY30121A1 (es) | 2006-02-03 | 2007-08-31 | Glaxo Group Ltd | Nuevos compuestos |
US8969394B2 (en) | 2006-08-11 | 2015-03-03 | Merck Frosst Canada Ltd. | Thiophenecarboxamide derivatives as EP4 receptor ligands |
JP5069752B2 (ja) | 2006-12-15 | 2012-11-07 | グラクソ グループ リミテッド | Ep4受容体アゴニストとしてのベンズアミド誘導体 |
EP2172447A4 (en) | 2007-07-03 | 2011-08-24 | Astellas Pharma Inc | amide |
GB0721611D0 (en) * | 2007-11-02 | 2007-12-12 | Glaxo Group Ltd | Novel compounds |
AU2009247262B2 (en) | 2008-05-14 | 2013-01-31 | Astellas Pharma Inc. | Amide compound |
KR20100107500A (ko) * | 2008-06-23 | 2010-10-05 | 테바 파마슈티컬 인더스트리즈 리미티드 | (s) 또는 (r)-이소-부틸-글루타릭 에스테르의 입체선택적 효소 합성방법 |
US20110287112A1 (en) | 2009-01-30 | 2011-11-24 | Ono Pharmaceutical Co., Ltd. | Prostate cancer progression inhibitor and progression inhibition method |
ES2698508T3 (es) | 2009-04-22 | 2019-02-05 | Askat Inc | Sustancia antagonista del receptor EP4 selectivo para el tratamiento del cáncer |
JP6152643B2 (ja) * | 2010-02-22 | 2017-06-28 | 株式会社AskAt | Il−23媒介疾患を治療するためのep4受容体拮抗薬の使用 |
JP5956448B2 (ja) * | 2010-09-21 | 2016-07-27 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 医薬組成物 |
EP2649061B1 (en) | 2010-12-10 | 2015-05-13 | Rottapharm Biotech S.r.l. | Pyridine amide derivatives as ep4 receptor antagonists |
ES2559513T3 (es) | 2011-07-04 | 2016-02-12 | Rottapharm Biotech S.R.L. | Derivados de amina cíclica como antagonistas del receptor EP4 |
WO2013032971A1 (en) | 2011-08-29 | 2013-03-07 | Ticona Llc | Melt-extruded substrate for use in thermoformed articles |
WO2013032981A1 (en) | 2011-08-29 | 2013-03-07 | Ticona Llc | High flow liquid crystalline polymer composition |
JP2014525498A (ja) | 2011-08-29 | 2014-09-29 | ティコナ・エルエルシー | 高流動性液晶ポリマー組成物 |
WO2013032974A1 (en) | 2011-08-29 | 2013-03-07 | Ticona Llc | Solid-state polymerization of a liquid crystalline polymer |
JP2014525499A (ja) | 2011-08-29 | 2014-09-29 | ティコナ・エルエルシー | 低い融解温度をもつ耐熱性液晶ポリマー組成物 |
CN103764741B (zh) | 2011-08-29 | 2015-09-23 | 提克纳有限责任公司 | 低熔体粘度液晶聚合物的熔融聚合 |
WO2013032967A1 (en) | 2011-08-29 | 2013-03-07 | Ticona Llc | Cast molded parts formed form a liquid crystalline polymer |
US9074133B2 (en) | 2011-08-29 | 2015-07-07 | Ticona Llc | Thermotropic liquid crystalline polymer with improved low shear viscosity |
CN103764623B (zh) | 2011-08-29 | 2016-04-27 | 提克纳有限责任公司 | 芳族酰胺化合物 |
JO3296B1 (ar) * | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
WO2014130275A2 (en) | 2013-02-22 | 2014-08-28 | Ticona Llc | High performance polymer composition with improved flow properties |
US10391086B2 (en) | 2013-03-19 | 2019-08-27 | Askat Inc. | Use of EP4 receptor antagonists in the treatment of cartilage disease |
CA2907049C (en) * | 2013-03-19 | 2021-08-10 | Askat Inc. | Use of ep4 receptor antagonists in the treatment of cartilage disease |
WO2014178891A1 (en) | 2013-04-30 | 2014-11-06 | Otitopic Inc. | Dry powder formulations and methods of use |
TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫-1h-異喹啉化合物 |
CN105358657A (zh) | 2013-06-07 | 2016-02-24 | 提克纳有限责任公司 | 高强度热致液晶聚合物 |
KR102212981B1 (ko) | 2013-06-12 | 2021-02-04 | 가껭세이야꾸가부시기가이샤 | 4-알키닐이미다졸 유도체 및 그것을 유효 성분으로서 함유하는 의약 |
AU2014366361B2 (en) * | 2013-12-17 | 2017-04-20 | Eli Lilly And Company | Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators |
CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
US10342785B2 (en) | 2016-11-04 | 2019-07-09 | Askat Inc. | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer |
HRP20211532T1 (hr) | 2017-05-18 | 2022-01-07 | Idorsia Pharmaceuticals Ltd | N-supstituirani derivati indola |
CN110612296A (zh) | 2017-05-18 | 2019-12-24 | 爱杜西亚药品有限公司 | 作为pge2受体调节剂的苯基衍生物 |
KR102626982B1 (ko) | 2017-05-18 | 2024-01-18 | 이도르시아 파마슈티컬스 리미티드 | Pge2 수용체 조절제로서의 피리미딘 유도체 |
JP7093791B2 (ja) | 2017-05-18 | 2022-06-30 | イドーシア ファーマシューティカルズ リミテッド | Pge2レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体 |
WO2018210992A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
SK592017A3 (sk) * | 2017-07-04 | 2019-01-08 | Saneca Pharmaceuticals A. S. | Spôsob prípravy morfínanových zlúčenín |
CN111315363B (zh) | 2017-09-22 | 2022-10-11 | 奥迪托皮克股份有限公司 | 含有硬脂酸镁的干粉组合物 |
US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
CN114075140A (zh) * | 2020-08-18 | 2022-02-22 | 武汉人福创新药物研发中心有限公司 | 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在癌症和炎症中的用途 |
WO2022102731A1 (ja) | 2020-11-13 | 2022-05-19 | 小野薬品工業株式会社 | Ep4拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19648793A1 (de) | 1996-11-26 | 1998-05-28 | Basf Ag | Neue Benzamide und deren Anwendung |
TW523506B (en) * | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
CA2285548C (en) | 1997-04-04 | 2006-07-11 | Pfizer Products Inc. | Nicotinamide derivatives |
US6211197B1 (en) * | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
EP1185508A2 (en) | 1999-05-24 | 2002-03-13 | Cor Therapeutics, Inc. | Inhibitors of factor xa |
US6924391B2 (en) * | 2000-05-11 | 2005-08-02 | Bristol-Myers Squibb Company | Alpha-amino,-thio,-oxo substituted ketones as phospholipase inhibitors |
ATE293109T1 (de) | 2001-01-31 | 2005-04-15 | Pfizer Prod Inc | Nikotinsäureamid-derivate und ihre mimetika als inhibitoren von pde4-isozyms |
HUP0401963A3 (en) | 2001-08-09 | 2006-01-30 | Ono Pharmaceutical Co | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
US20050009812A1 (en) | 2001-10-05 | 2005-01-13 | Takuya Seko | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists |
-
2005
- 2005-04-22 KR KR1020067023128A patent/KR20070006891A/ko active IP Right Grant
- 2005-04-22 CA CA2565813A patent/CA2565813C/en active Active
- 2005-04-22 AP AP2006003785A patent/AP2006003785A0/xx unknown
- 2005-04-22 JP JP2007512542A patent/JP4054368B2/ja active Active
- 2005-04-22 AU AU2005238291A patent/AU2005238291A1/en not_active Abandoned
- 2005-04-22 CN CNA2005800141028A patent/CN1950333A/zh active Pending
- 2005-04-22 EP EP05733780.0A patent/EP1756042B8/en active Active
- 2005-04-22 BR BRPI0510666-4A patent/BRPI0510666A/pt not_active IP Right Cessation
- 2005-04-22 MX MXPA06011555A patent/MXPA06011555A/es active IP Right Grant
- 2005-04-22 ES ES05733780.0T patent/ES2461265T3/es active Active
- 2005-04-22 WO PCT/IB2005/001134 patent/WO2005105732A1/en active Application Filing
- 2005-04-22 EA EA200601847A patent/EA200601847A1/ru unknown
- 2005-04-27 PA PA20058631201A patent/PA8631201A1/es unknown
- 2005-04-29 UY UY28877A patent/UY28877A1/es not_active Application Discontinuation
- 2005-04-29 US US11/118,497 patent/US7534914B2/en not_active Expired - Fee Related
- 2005-04-29 DO DO2005000071A patent/DOP2005000071A/es unknown
- 2005-05-02 AR ARP050101745A patent/AR048642A1/es unknown
- 2005-05-03 NL NL1028947A patent/NL1028947C2/nl not_active IP Right Cessation
- 2005-05-03 TW TW094114245A patent/TW200536541A/zh unknown
- 2005-05-03 GT GT200500101A patent/GT200500101A/es unknown
- 2005-05-03 PE PE2005000493A patent/PE20060306A1/es not_active Application Discontinuation
- 2005-05-04 SV SV2005002102A patent/SV2005002102A/es not_active Application Discontinuation
-
2006
- 2006-10-06 ZA ZA200608393A patent/ZA200608393B/en unknown
- 2006-10-17 IL IL178676A patent/IL178676A0/en unknown
- 2006-11-01 EC EC2006006968A patent/ECSP066968A/es unknown
- 2006-11-03 MA MA29436A patent/MA28571B1/fr unknown
- 2006-11-03 TN TNP2006000358A patent/TNSN06358A1/fr unknown
- 2006-11-03 CR CR8730A patent/CR8730A/es not_active Application Discontinuation
- 2006-12-04 NO NO20065578A patent/NO20065578L/no not_active Application Discontinuation
-
2009
- 2009-02-10 US US12/368,778 patent/US8084476B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0510666A (pt) | compostos de amida de arila ou heteroarila de metila substituìda, composições farmacêuticas compreendendo os mesmos, uso e combinação | |
BRPI0510598A (pt) | compostos de amida de aril ou heteroaril substituìdos | |
BRPI0414130B8 (pt) | compostos de fenilamida ou piridilamida, seu uso e composições farmacêuticas que os compreendem. | |
BRPI0409241A (pt) | compostos bicìclicos como antagonistas do receptor de nr2b, composições farmacêuticas compreendendo os mesmos e seu uso | |
BRPI0615111B8 (pt) | composto, composição farmacêutica, e, uso do composto | |
DE602005004286D1 (de) | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyridoä2,3-düpyrimidinderivate und verwandte verbindungen zur behandlung von krebs | |
BRPI0517423A (pt) | composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto | |
BRPI0707491B8 (pt) | compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas | |
BR112012033770A2 (pt) | novo derivado de nicotinamida ou sal do mesmo | |
BRPI0511132A (pt) | derivados de pirimidina e composição farmacêutica compreendendo os mesmos | |
BRPI0507495A (pt) | composto, composição farmacêutica, uso do composto método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5 | |
ATE388146T1 (de) | 1-isopropyl-2-oxo-1,2-dihydropyridin-3- carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor | |
BRPI0513858A (pt) | compostos de benziltriazolona como inibidores não-nucleosìdeos da transcriptase reversa | |
BR0014137A (pt) | Composto, método para inibir a aurora 2 quinase em um animal de sangue quente, uso de um composto, e, composição farmacêutica | |
PE20090151A1 (es) | Derivados de pirimidinona y metodos para su uso | |
BRPI0509377A (pt) | compostos de ácido alfa arila ou heteroaril metil beta piperidino propanóico como antagonistas do receptor orl1 | |
BRPI0921701B8 (pt) | Cefarosporina tendo um grupo catecol, seu uso e composição farmacêutica que a compreende | |
BRPI0409227B8 (pt) | "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)" | |
BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
BRPI0607353A2 (pt) | composto de fórmula (i); composição farmacêutica; uso do composto para o tratamento ou controle de infecções bacterianas em animais de sangue quente; processo para a preparação de tetraciclinas 9-(n-substituìdas-n-substituìdas-glicil) de fórmulas 5; 7; 10; e tetraciclina 9-(n-substituìda-n-substituìda glicil) de fómulas 5; 7; 10 | |
NO20076425L (no) | Fremgangsmater for behandling av drug-resistent cancer | |
BR0314363A (pt) | Indóis 2,4-substituìdos e seu uso como moduladores de 5-ht6 | |
EA014959B3 (ru) | Ингибиторы глицинового переносчика-1 | |
BR0314352A (pt) | Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6 | |
GEP20074256B (en) | Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A,5A E 6A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE A 8.6 NA RPI 2099 DE 29/03/2011. |